UK medicinal cannabis investor Sativa Investments PLC (AQSE: SATI) has teamed up with King's College London to research the impact of cannabinoids on inflammation and respiratory diseases.
Under the research agreement, Sativa will supply the university with specific strains of cannabis plants that contain various combinations of the spectrum of at least 113 known cannabinoids, subject to regulatory approval.
READ: Sativa Investments completes 1000th cannabinoid and terpenes test at PhytoVista facility
Sativa will provide the service through investee business, Canada-based Veritas Pharma Inc, and its own on-site testing facility, PhytoVista Laboratories.
Professor Clive Page OBE PhD Professor of Pharmacology at King's College London will lead the research.
"With the UK catching up fast in terms of recognising the benefits of medicinal cannabis, in-country research from the globally-recognised King's College London will assist the medical profession, Government and Regulators in their deliberations,” said Sativa founder and chief executive, Geremy Thomas.
"As the UK's first medicinal cannabis investment vehicle, Sativa remains at the forefront of this fast-developing sector, which effectively mirrors what has been happening in North America since medicinal cannabis was first legalised in Canada in 2001, more than 17 years ago.”
